Pig pancreatic cell transplant improved outcomes in diabetics

05/7/2010 | Bloomberg Businessweek

No adverse events or immune system reactions were seen in patients with Type 1 diabetes who were transplanted with encapsulated pig pancreatic cells, according to a New Zealand study. After the treatment, two people were able to halt insulin shots for four weeks and 32 weeks, respectively, while others were able to lessen their daily insulin needs, the study also showed. The transplanted cells work by producing insulin in response to the high sugar levels in the patients' blood.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA